av Mika Falck-Hansen | jan 6, 2021
BUSINESS OPPORTUNITY This new CAR T-cell can be developed to treat children and adults with B cell lymphoma. Inven2 is seeking to out-license the technology to pharmaceutical companies and/or biotechnology SMEs for clinical trials either as a single intervention or...
av Mika Falck-Hansen | des 15, 2020
Business opportunity The present technology has the potential to effectively treat children and adults with metastatic osteosarcoma (bone cancer) where the disease has progressed beyond the first and second line treatment. Inven2 seeks collaboration with industrial...
av Kim Larsen | jun 29, 2020
Business opportunity Inventors at the University of Oslo/Oslo University Hospital have developed an engineered human albumin variant with extended in vivo half-life. This unique albumin can be used as a fusion partner to improve the pharmacokinetics of...
av Kim Larsen | jun 29, 2020
Business opportunity Inventors at the University of Oslo/Oslo University Hospital have developed a novel technology for enhanced uptake of subunit vaccines across mucosal barriers. This technology is built on an engineered human albumin variant with increased mucosal...
av Kim Larsen | jun 29, 2020
Business opportunity Inventors at the University of Oslo/Oslo University hospital have developed a unique and versatile antibody Fc technology platform (“REW”). The technology increases the serum half-life and biodistribution properties of IgG antibodies and Fc...
